Thursday, November 21, 2024
11/21/2024
PROJECT SUMMARY Human papillomavirus (HPV) is the causative agent of 5% of all human cancers, including 25% of head and neck squamous cell carcinomas (HNSCCs). HPV-driven disease progression requires both persistent infection and evasion of the host immune response. One mechanism of immune evasion employed by many cancers, including HPV+ HNSCCs, is the downregulation of major histocompatibility complex class I (MHC-I) on the surface of tumor cells. MHC-I antigen presentation is crucial for recognition of tumor cells by CD8+ T cells during the antitumor response and is a major contributor to lack of patient response to immune checkpoint inhibitor therapy. Our lab has previously shown that an E3 ubiquitin ligase upregulated in HPV+ HNSCCs, MARCHF8, ubiquitinates immune surface receptors, including MHC-I, for subsequent degradation. Further, a genome wide CRISPR screen identified genes involved in autophagy, a cellular degradation pathway, as candidates for negative regulators of MHC-I. Based on these findings, I hypothesize that MARCHF8 upregulation by papillomaviruses promotes immune evasion by directing MHC-I for autophagic degradation. To test this hypothesis, I will 1) investigate the mechanism of MARCHF8-mediated MHC-I ubiquitination and degradation via the autophagy pathway and 2) evaluate inhibition of autophagy as a novel treatment for HPV+ HNSCC. With these aims, this project will uncover a mechanism of immune evasion during papillomavirus-induced carcinogenesis.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
